www.reuters.com Open in urlscan Pro
2600:9000:235a:f800:15:5a3e:9d40:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content

Exclusive news, data and analytics for financial market professionalsLearn more
aboutRefinitiv

Reuters home
 * World
   Browse World
    * Africa
    * Americas
    * Asia Pacific
    * China
    * Europe
    * India
    * Israel and Hamas at War
   
    * Japan
    * Middle East
    * Ukraine and Russia at War
    * United Kingdom
    * United States
    * US Election
    * Reuters Next
   
   Latest in World
    * North Korean leader revisits flooded area, offers plan to bring people to
      capital, KCNA says
      6 min ago
      
    * Iran set to carry out leader's order to 'harshly punish' Israel, Guards
      deputy chief says
      20 min ago
      
    * US tells Israel that escalations in Middle East serve no one
      26 min ago
      
    * Iraqi teen held in Vienna after Taylor Swift attack plot foiled
      44 min ago
      

 * Business
   Browse Business
    * Aerospace & Defense
    * Autos & Transportation
    * Davos
    * Energy
    * Environment
    * Finance
    * Healthcare & Pharmaceuticals
   
    * Media & Telecom
    * Retail & Consumer
    * Future of Health
    * Future of Money
    * Take Five
    * World at Work
   
   Latest in Business
    * Tesla stops taking orders for cheapest Cybertruck, offers $100,000 version
      now
      25 min ago
      
    * US retailers rush holiday imports, fearing strikes and disruptions
      an hour ago
      
    * Meta beats censorship lawsuit by RFK Jr's anti-vaccine group
      1:36 AM GMT+2
      
    * 'Coerced' JPMorgan Chase seeks to end NY lawsuit against Russia's VTB Bank
      1:04 AM GMT+2
      

 * Markets
   Browse Markets
    * Asian Markets
    * Carbon Markets
    * Commodities
    * Currencies
    * Deals
    * Emerging Markets
    * ETFs
    * European Markets
   
    * Funds
    * Global Market Data
    * Rates & Bonds
    * Stocks
    * U.S. Markets
    * Wealth
    * Macro Matters
   
   Latest in Markets
    * Hedge funds pile into bearish Japanese stock bets, bank says
      August 9, 2024
      
    * Take Five: Cruel summer
      August 9, 2024
      
    * TSX posts weekly gain as markets recover from 'oversold' levels
      August 9, 2024
      
    * Canada sheds 2,800 jobs in July, jobless rate stays at 6.4%
      August 9, 2024
      

 * Sustainability
   Browse Sustainability
    * Boards, Policy & Regulation
    * Climate & Energy
    * Land Use & Biodiversity
    * Society & Equity
    * Sustainable Finance & Reporting
    * The Switch
    * Reuters Impact
   
   Latest in Sustainability
    * Meta beats censorship lawsuit by RFK Jr's anti-vaccine group
      1:36 AM GMT+2
      
    * Argentina grains workers strike could continue beyond Friday
      12:29 AM GMT+2
      
    * Activist Starboard Value takes stake in Starbucks, WSJ reports
      12:09 AM GMT+2
      
    * Canada railways warn of Aug. 22 lockout without labor deal
      12:08 AM GMT+2
      

 * Legal
   Browse Legal
    * Government
    * Legal Industry
    * Litigation
    * Transactional
    * US Supreme Court
   
   Latest in Legal
    * Meta beats censorship lawsuit by RFK Jr's anti-vaccine group
      1:36 AM GMT+2
      
    * Federal court extends block on Biden's student debt relief plan
      1:05 AM GMT+2
      
    * 'Coerced' JPMorgan Chase seeks to end NY lawsuit against Russia's VTB Bank
      1:04 AM GMT+2
      
    * Finch wins US jury trial against Ferring over fecal-transplant patents
      12:25 AM GMT+2
      

 * Breakingviews
   Browse Breakingviews
    * Breakingviews Predictions
   
   Latest in Breakingviews
    * Court-emboldened capital puts labor on front lines
      August 9, 2024
      
    * Jay Powell excels at his top job: punching bag
      August 9, 2024
      
    * UK wealth buyout requires elbow grease and luck
      August 9, 2024
      
    * KKR shows it's business as usual in Japan Inc
      August 9, 2024
      

 * Technology
   Browse Technology
    * Artificial Intelligence
    * Cybersecurity
    * Space
    * Disrupted
   
   Latest in Technology
    * Can online voting be secure? Experts in Las Vegas try to hack new platform
      an hour ago
      
    * Meta beats censorship lawsuit by RFK Jr's anti-vaccine group
      1:36 AM GMT+2
      
    * Chinese rocket's breakup puts over 1,000 satellites and other objects at
      risk
      12:02 AM GMT+2
      
    * UK revisits social media regulation after far-right riots
      August 9, 2024
      

 * Investigations
 * More
   Sports
    * Olympics
    * Athletics
    * Baseball
    * Basketball
    * Cricket
    * Cycling
    * Formula 1
    * Golf
    * NFL
    * NHL
    * Soccer
    * Tennis
   
   Science
   Lifestyle
   Graphics
   Pictures
   Podcasts
   Fact Check
   Video
   Sponsored Content
    * Reuters Plus
    * Press Releases
   
   Trending Stories
    * Worldcategory
      Bangladesh's Hasina did not resign before fleeing, son says
      
    * Sportscategory
      South Korea pistol shooter Kim Ye-ji collapses at press conference
      
    * Worldcategory
      Sao Paulo plane crash: All 61 on board killed
      
    * Exclusive: Iran to deliver hundreds of ballistic missiles to Russia soon,
      intel sources say
      

My News

Sign InRegister

 * Healthcare & Pharmaceuticals
 * Health
 * Public Health


DEVELOPERS OF VAPES FOR MIGRAINE, ASTHMA WILL NEED TO WIN OVER SCEPTICS

By Emma Rumney
August 9, 20244:08 PM GMT+2Updated 11 hours ago
Text
 * Small Text
 * Medium Text
 * Large Text

Share
 * X
 * Facebook
 * Linkedin
 * Email
 * Link

Item 1 of 5 A mock-up of Qnovia's nicotine replacement therapy device RespiRx.
Qnovia/Handout via REUTERS
[1/5]A mock-up of Qnovia's nicotine replacement therapy device RespiRx.
Qnovia/Handout via REUTERS Purchase Licensing Rights, opens new tab

 * Companies

 * Altria Group Inc
   Follow
 * GSK plc
   Follow
 * Philip Morris International Inc
   Follow

LONDON, Aug 9 (Reuters) - A handful of North American companies which see
potential for vape-like devices to ease migraines and respiratory diseases such
as asthma have a long road to convince health authorities and patients that
their products can be the future of inhaled medication.
Two companies, Qnovia and MIIST Therapeutics, have developed vape-like devices
based on technology used in existing medical nebulisers, which turns liquid
medications into a fine mist.
Advertisement · Scroll to continue

Another company, Greentank, says it has developed a way to vaporise substances
via a heating chip that addresses safety concerns with current vapes and may
offer a better way to treat ailments like migraines.
The companies and experts say inhalation can relieve pain in seconds, with fewer
side effects than pills, but their ambitions to sell devices resembling vapes in
the medical sphere, amid growing concerns about their health impacts, will be a
tough task.
Advertisement · Scroll to continue

For now, Qnovia and MIIST will launch their products initially as
prescription-only nicotine replacement therapy (NRT) treatments, while Greentank
is initially targeting the use of its heating chip in recreational cannabis and
nicotine vapes.
The companies ultimately aim to see their devices delivering a wide range of
drugs and Douglas Dunlap, chief commercial officer at Greentank, cites migraine
medication as an example.

A common method of administering migraine treatment is via a pill, which takes
up to an hour to kick in and can include symptoms such as vomiting and
dizziness.
"If we could shorten that, it would be a huge success for us," said Dunlap, a
former executive at vape gaint JUUL, adding vapes can deliver a hit within 60
seconds.
Three billion people globally suffer from migraines, according to the World
Health Organization. Hundreds of millions more have conditions like asthma or
pulmonary diseases, treated with inhaled medications.

Pharmaceutical company GSK (GSK.L), opens new tab alone generated almost 7
billion pounds ($8.9 billion) of revenue from general respiratory medicines for
conditions such as asthma and pulmonary diseases in 2023.


HEALTH CONCERNS

Federico Buonocore, a professor focused on alternative pulmonary drug delivery
at Kingston University in Britain, said existing inhaled drug delivery devices
are clunky and difficult to operate, and so tend to be used wrongly.

A vape-like design could solve such challenges, he said.
Big Tobacco firms have already tried and failed to tap into this market, their
efforts fraught by mistrust and opposition from health officials.
Philip Morris International (PM.N), opens new tab last year scrapped a goal to
earn over $1 billion in annual revenue by 2025 from its wellness and healthcare
unit, which includes a business making asthma inhalers.
CEO Jacek Olczak said the company had been "too optimistic about how the
external environment will accept... Big Tobacco" in industries outside of
nicotine. An inhaled aspirin product developed by the unit was also deemed
unsuccessful after a clinical trial last year.
Virginia-based Qnovia and California-based MIIST are pharmaceutical firms and
not associated with Big Tobacco, although some of their top executives came from
that industry.
Qnovia CEO Brian Quigley, a former boss of tobacco giant Altria (MO.N), opens
new tab, told Reuters the company plans to submit drug applications in the U.S.
soon and the United Kingdom in 2026 for its device as an NRT, and launch a
clinical trial in September.
MIIST also needs to secure regulatory approvals. Its Phase 1 clinical trial
found its device could ease cravings faster than other approved NRTs like
patches and gums - notoriously ineffective in helping smokers quit.

Reuters Graphics
Toronto-based Greentank, which was founded in 2015 to make vaping hardware, will
see the first U.S. cannabis vape using its technology launched in September by
U.S. company Jaunty.
Greentank is now looking for a pharmaceutical partner to support the development
of its heating chip for medicine delivery.
MIIST founder Dalton Signor told Reuters he hopes the company's device could one
day be used to administer drugs for things like pain and anxiety relief.
However, he said a major challenge is ensuring devices like MIIST's are not
conflated with typical vapes - the subject of growing health concerns.
Authorities like the World Health Organization say vapes can produce harmful
chemicals like formaldehyde and heavy metals, and their long-term impacts are
uncertain.
Venture capital investor Catharine Dockery, CEO of Vice Ventures, said her firm
backed Qnovia because its nebuliser technology does not use heat, a process that
can result in harmful emissions.
Greentank's device does use heat - a fact that also means some drugs may not
work with it.
Dunlap said Greentank is in the early stages of trying to identify medicines
that are suited to the technology, and testing shows its heating method does not
result in any harmful emissions.
But many may remain sceptical.
Kingston University's Buonocore researched the use of e-cigarettes as drug
delivery devices.
"The first thing everyone told me was: 'It is wrong to use this device as a
medical device'," he said, adding that concerns included that it would be
inappropriate to prescribe them to children.
"Coming out of that stigma is going to be very difficult for the sector."
($1 = 0.7867 pounds)

Keep up with the latest medical breakthroughs and healthcare trends with the
Reuters Health Rounds newsletter. Sign up here.

Reporting by Emma Rumney; Editing by Matt Scuffham and Susan Fenton

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Share
 * X
 * Facebook
 * Linkedin
 * Email
 * Link

Purchase Licensing Rights


READ NEXT

 * Regulatory OversightcategoryUS FDA declines to approve first MDMA-based PTSD
   treatment
 * Healthcare & PharmaceuticalscategoryUS FDA approves nasal spray alternative
   to EpiPen for allergic reactions
 * Regulatory OversightcategoryUS FDA extends review of Humacyte's blood vessel
   implant
 * Public HealthcategoryMichigan reports human case of swine flu
 * Healthcare & PharmaceuticalscategoryUS FDA approves Citius' therapy for rare
   blood cancer




BUSINESS


 * TESLA STOPS TAKING ORDERS FOR CHEAPEST CYBERTRUCK, OFFERS $100,000 VERSION
   NOW
   
   ADAS, AV & Safetycategory · August 10, 2024 · 2:30 AM GMT+2 · 25 min ago
   
   Tesla has stopped taking orders for the least expensive version of its
   Cybertruck, which is priced at $61,000, while making the $100,000 version
   available for immediate order and delivery as soon as this month, its website
   showed.

 * Retail & ConsumercategoryUS retailers rush holiday imports, fearing strikes
   and disruptions2:00 AM GMT+2 · Updated an hour ago
 * LegalcategoryMeta beats censorship lawsuit by RFK Jr's anti-vaccine group1:36
   AM GMT+2
 * Legalcategory'Coerced' JPMorgan Chase seeks to end NY lawsuit against
   Russia's VTB Bank1:04 AM GMT+2
 * categoryS&P 500 ends up, but near flat for week after Monday's steep
   selloff1:02 AM GMT+2




SITE INDEX


LATEST

 * Home
 * Authors
 * Topic sitemap
 * Archive
 * Sitemap


BROWSE

 * World
 * Business
 * Markets
 * Sustainability
 * Legal
 * Breakingviews
 * Technology
 * Investigations
 * Sports
 * Science
 * Lifestyle


MEDIA

 * 
   Videos
 * 
   Pictures
 * 
   Graphics


ABOUT REUTERS

 * About Reuters, opens new tab
 * Careers, opens new tab
 * Reuters News Agency, opens new tab
 * Brand Attribution Guidelines, opens new tab
 * Reuters Leadership, opens new tab
 * Reuters Fact Check
 * Reuters Diversity Report, opens new tab


STAY INFORMED

 * Download the App (iOS), opens new tab
 * Download the App (Android), opens new tab
 * Newsletters


INFORMATION YOU CAN TRUST

Reuters, the news and media division of Thomson Reuters, is the world’s largest
multimedia news provider, reaching billions of people worldwide every day.
Reuters provides business, financial, national and international news to
professionals via desktop terminals, the world's media organizations, industry
events and directly to consumers.


FOLLOW US

 * X
 * Facebook
 * Instagram
 * Youtube
 * Linkedin


THOMSON REUTERS PRODUCTS

 * WESTLAW, OPENS NEW TAB
   
   BUILD THE STRONGEST ARGUMENT RELYING ON AUTHORITATIVE CONTENT,
   ATTORNEY-EDITOR EXPERTISE, AND INDUSTRY DEFINING TECHNOLOGY.

 * ONESOURCE, OPENS NEW TAB
   
   THE MOST COMPREHENSIVE SOLUTION TO MANAGE ALL YOUR COMPLEX AND EVER-EXPANDING
   TAX AND COMPLIANCE NEEDS.

 * CHECKPOINT, OPENS NEW TAB
   
   THE INDUSTRY LEADER FOR ONLINE INFORMATION FOR TAX, ACCOUNTING AND FINANCE
   PROFESSIONALS.


LSEG PRODUCTS

 * WORKSPACE, OPENS NEW TAB
   
   ACCESS UNMATCHED FINANCIAL DATA, NEWS AND CONTENT IN A HIGHLY-CUSTOMISED
   WORKFLOW EXPERIENCE ON DESKTOP, WEB AND MOBILE.

 * DATA CATALOGUE, OPENS NEW TAB
   
   BROWSE AN UNRIVALLED PORTFOLIO OF REAL-TIME AND HISTORICAL MARKET DATA AND
   INSIGHTS FROM WORLDWIDE SOURCES AND EXPERTS.

 * WORLD-CHECK, OPENS NEW TAB
   
   SCREEN FOR HEIGHTENED RISK INDIVIDUAL AND ENTITIES GLOBALLY TO HELP UNCOVER
   HIDDEN RISKS IN BUSINESS RELATIONSHIPS AND HUMAN NETWORKS.

 * Advertise With Us, opens new tab
 * Advertising Guidelines
 * Purchase Licensing Rights, opens new tab

 * Cookies, opens new tab
 * Terms of Use
 * Privacy, opens new tab
 * Digital Accessibility, opens new tab
 * Corrections
 * Site Feedback, opens new tab

All quotes delayed a minimum of 15 minutes. See here for a complete list of
exchanges and delays.

© 2024 Reuters. All rights reserved






RIGHT TO WITHDRAW CONSENT UNDER GDPR

We and our 152 partners store and/or access information on a device, such as
unique IDs in cookies to process personal data. You may accept or manage your
choices by clicking below, including your right to object where legitimate
interest is used, or at any time in the privacy policy page. These choices will
be signaled to our partners and will not affect browsing data.Cookie
PolicyPrivacy Statement


WE AND OUR PARTNERS PROCESS DATA TO PROVIDE:

Use precise geolocation data. Actively scan device characteristics for
identification. Store and/or access information on a device. Personalised
advertising and content, advertising and content measurement, audience research
and services development. List of Partners (vendors)

Allow All Reject All Show Purposes


Feedback